AML Assays in Primary Patient Samples
Vivia Biotech can
significantly enhance
AML drug profiling
processes thanks to
our access to
biological samples
from real patients.
- Vivia Biotech has access to primary samples from patients diagnosed with a variety of hematological malignancies including AML and can provide extremely valuable data making the difference in your drug development pipeline.
Vivia AML Ex Vivo Assays in a Nutshell…
We have specific assays to cover the different mechanisms of action of many drugs and compounds and to capture
the effects of apoptosis, necrosis, cell cycle arrest, proliferation, immune cell modulation, or antibody-dependent
cellular cytotoxicity, between others, directly on patient samples.
Our key innovations supply sound pharmacology using real AML patient samples.
Vivia as Your Companion Diagnostic Clinical Trial in AML
- We have developed a precision medicine (PM) ex vivo test with 92% patients predicted to be sensitive and 75% overall survival at 3 years with a backbone first line treatment in AML patients
- Using this PM ex vivo test we have analyzed a novel Otsuka drug as CDx clinical trial
- A biomarker-driven design was used in a phase Ib clinical trial for the upfront identification and enrollment of AML patients based on the highest sensitivity to the Otsuka drug, discarding those hypothetically resistant ones and thus minimizing the likelihood of treatment failures.